RecruitingNCT06794970
Tissue Study on the Chronic Active Humoral Rejection (cAMR) Population of Kidney Transplantation
Sponsor
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Enrollment
50 participants
Start Date
May 1, 2023
Study Type
OBSERVATIONAL
Conditions
Summary
The study is tissue-based, retrospective and prospective, single-centre, non-sponsored. Primary objective: To examine patient and organ survival and eGFR variation in kidney transplant patients diagnosed histologically with cAMR.
Eligibility
Min Age: 18 Years
Inclusion Criteria5
- Age ≥18 years
- Kidney transplant recipients
- eGFR>15 ml/min/1.73 sq m at the time of diagnosis of cAMR
- cAMR diagnosis defined on the basis of the 2018 Banff Classification (17), made after 1/1/2018.
- Obtaining Informed Consent to Participation.
Exclusion Criteria2
- Combined transplant patients (heart-kidney, liver-kidney or kidney-pancreas)
- Histological evidence of concomitant disease (e.g. recurrence of original nephropathy or diagnosis of 'de novo' nephropathy, acute cellular rejection, polyomavirus BK nephropathy, other)
Interested in this trial?
Get notified about updates and connect with the research team.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06794970
Related Trials
Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Ravulizumab Administered Intravenously in Adult Participants at High Risk of Delayed Graft Function After Kidney Transplantation
NCT06830798130 locations
Empagliflozin Treatment in Kidney Transplant Recipients
NCT060138655 locations
Personalized Stories for Pediatric Kidney Recipients
NCT075323821 location
Tacrolimus and Risk Factors for Glucose Metabolism Disorders in Kidney Transplant Patients
NCT068334636 locations
Kidney Protective Jacket
NCT073484581 location